Business
RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright’s 26th Annual Global Investment Conference on September 9, 2024 in New York
LOS ALTOS, Calif., Aug. 27, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company
About this update from Renovorx, Inc.
[{"type":"text","content":"LOS ALTOS, Calif., Aug. 27, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced that Shaun Bagai, Chief Executive Officer, will present at H.C. Wainwright’s 26th Annual Global Investment Conference being held at the Lotte New York Palace Hotel in New York City. The conference will be held September 9-11, 2024, with Mr. Bagai’s presentation on September 9, 2024, at 7:00 a.m. ET. Mr. Bagai will discuss recent corporate achievements including progress on RenovoRx’s pivotal ongoing Phase III TIGeR-PaC clinical trial evaluating the proprietary TAMP™ (Trans-Arterial Micro-Perfusion) therapy platform for the treatment of Locally Advanced Pancreatic Cancer (LAPC.) He will also discuss RenovoRx’s ongoing exploration of new commercial business development opportunities with its proprietary therapy platform technology and FDA-cleared RenovoCath® delivery system as a stand-alone device. RenovoCath is indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. In connection with this effort, RenovoRx appointed Ryan Witt as Senior Vice President of Corporate Strategy and Partnerships in June 2024. Presentation Details: Date: Monday, September 9, 2024Time: 7:00 a.m. ETLocation: Lotte New York Palace Hotel, New YorkSpeaker: Shaun Bagai, CEOWebcast: https://journey.ct.events/view/c647b446-97cc-44c8-9cbf-37b1af70039c To schedule a one-on-one investor meeting with Mr. Bagai, please contact your H.C. Wainwright representative or KCSA Strategic Communications at [email protected]. A replay of this presentation will be available for 90 days following the date of the presentation on the Company’s website at https://ir.renovorx.com/news-events/ir-calendar-events. About the TIGeR-PaC Clinical Trial TIGeR-PaC is an ongoing Phase III randomized multi-center study evaluating the proprietary TAMP™ (Trans-Arterial Micro-Perfusion) therapy platform for the treatment of Locally Advanced Pancreatic Cancer (LAPC.) RenovoRx’s first product candidate using the TAMP technology, is a novel investigational oncology drug-delivery combination utilizing the Company’s FDA-cleared RenovoCath® device for the intra-a...